Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.07 -2.7%	$0.96	$0.69 ▼ $3.94	$218.02M	0.67	5.20 million shs	5.15 million shs
NBTX Nanobiotix	$4.47 +4.2%	$3.89	$2.76 ▼ $6.00	$202.20M	0.36	15,769 shs	2,954 shs
SGTX Sigilon Therapeutics	$22.47	$22.02	$3.77 ▼ $28.00	$56.40M	4.12	62,902 shs	N/A
YMAB Y-mAbs Therapeutics	$4.41 -4.8%	$4.46	$3.55 ▼ $16.11	$209.66M	0.52	304,802 shs	764,472 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	-2.73%	-8.55%	+25.44%	-36.69%	-60.66%
NBTX Nanobiotix	+2.05%	-13.20%	+19.04%	+23.48%	-1.54%
SGTX Sigilon Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
YMAB Y-mAbs Therapeutics	-4.75%	-6.37%	+7.56%	-11.80%	-62.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.0918 of 5 stars	3.4	3.0	0.0	3.9	2.5	1.7	0.6
NBTX Nanobiotix	2.1792 of 5 stars	3.3	5.0	0.0	0.0	1.1	0.0	0.6
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	2.7188 of 5 stars	4.4	2.0	0.0	0.0	0.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	554.21% Upside
NBTX Nanobiotix	2.50	Moderate Buy	$8.00	78.97% Upside
SGTX Sigilon Therapeutics	0.00	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	2.82	Moderate Buy	$15.60	253.74% Upside

Current Analyst Ratings Breakdown

Latest SGTX, YMAB, NBTX, and ESPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$20.00 ➝ $15.00
5/28/2025	YMAB Y-mAbs Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$21.00 ➝ $18.00
5/19/2025	YMAB Y-mAbs Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $11.00
5/14/2025	YMAB Y-mAbs Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $14.00
5/14/2025	YMAB Y-mAbs Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/22/2025	YMAB Y-mAbs Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.64	$0.02 per share	45.78	($1.97) per share	-0.54
NBTX Nanobiotix	$39.18M	5.38	N/A	N/A	($1.51) per share	-2.96
SGTX Sigilon Therapeutics	$12.94M	4.36	N/A	N/A	$15.68 per share	1.43
YMAB Y-mAbs Therapeutics	$87.68M	2.28	N/A	N/A	$2.05 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
NBTX Nanobiotix	-$73.73M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
SGTX Sigilon Therapeutics	-$43.56M	-$12.23	N/A	N/A	N/A	-171.29%	-83.07%	-38.17%	N/A
YMAB Y-mAbs Therapeutics	-$29.67M	-$0.64	N/A	N/A	N/A	-31.84%	-30.59%	-22.70%	8/11/2025 (Estimated)

Latest SGTX, YMAB, NBTX, and ESPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/13/2025	Q1 2025	YMAB Y-mAbs Therapeutics	-$0.22	-$0.12	+$0.10	-$0.12	$19.97 million	$20.90 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
NBTX Nanobiotix	N/A	N/A	N/A	N/A	N/A
SGTX Sigilon Therapeutics	N/A	N/A	N/A	N/A	N/A
YMAB Y-mAbs Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
NBTX Nanobiotix	N/A	1.04	1.04
SGTX Sigilon Therapeutics	N/A	1.78	1.78
YMAB Y-mAbs Therapeutics	N/A	4.77	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
NBTX Nanobiotix	38.81%
SGTX Sigilon Therapeutics	N/A
YMAB Y-mAbs Therapeutics	70.85%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
NBTX Nanobiotix	3.45%
SGTX Sigilon Therapeutics	6.50%
YMAB Y-mAbs Therapeutics	19.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
NBTX Nanobiotix	100	47.13 million	45.51 million	Not Optionable
SGTX Sigilon Therapeutics	62	2.51 million	2.35 million	Not Optionable
YMAB Y-mAbs Therapeutics	150	45.28 million	36.36 million	Optionable

SGTX, YMAB, NBTX, and ESPR Headlines

Recent News About These Companies

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $15.60 Consensus PT from Brokerages

June 12, 2025 | americanbankingnews.com

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

June 11, 2025 | finance.yahoo.com

Wesbanco Bank Inc. Acquires Shares of 55,000 Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Comments on YMAB FY2026 Earnings

June 10, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Moderate Buy" from Analysts

June 9, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Bank of America Corp DE

June 8, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Lowered to $15.00 at Oppenheimer

May 30, 2025 | marketbeat.com

Wedbush Reiterates Outperform Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

May 29, 2025 | marketbeat.com

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

May 28, 2025 | globenewswire.com

Infinitum Asset Management LLC Purchases New Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

May 28, 2025 | marketbeat.com

Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025

May 26, 2025 | insidermonkey.com

Y-mAbs Therapeutics Presents GD2-SADA Data at Advances in Neuroblastoma Research Meeting

May 26, 2025 | quiverquant.com

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

May 26, 2025 | globenewswire.com

Y-mAbs Therapeutics’ SWOT analysis: antibody innovator’s stock faces growth hurdles

May 24, 2025 | investing.com

HC Wainwright Brokers Decrease Earnings Estimates for YMAB

May 23, 2025 | marketbeat.com

FY2026 Earnings Forecast for YMAB Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

May 21, 2025 | marketbeat.com

Truist Financial Sticks to Its Buy Rating for Y-Mabs Therapeutics (YMAB)

May 16, 2025 | theglobeandmail.com

Y-mAbs Therapeutics Inc (YMAB) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges

May 14, 2025 | finance.yahoo.com

Y-mAbs Therapeutics, Inc.: Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

May 13, 2025 | finanznachrichten.de

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGTX, YMAB, NBTX, and ESPR Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.07 -0.03 (-2.73%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.07 +0.00 (+0.37%)

As of 06/20/2025 07:09 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Nanobiotix NASDAQ:NBTX

$4.47 +0.18 (+4.20%)

Closing price 06/20/2025 03:57 PM Eastern

Extended Trading

$4.47 0.00 (0.00%)

As of 06/20/2025 05:40 PM Eastern

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.

Sigilon Therapeutics NASDAQ:SGTX

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Y-mAbs Therapeutics NASDAQ:YMAB

$4.41 -0.22 (-4.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.45 +0.04 (+0.88%)

As of 06/20/2025 04:51 PM Eastern

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time